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The discovery of insulin represents an authentic breakthrough, characterized, at the
same time, by contrasts, controversies and disputes among scholars, as well as by
great disappointments, failures and hopes. It is the story of famous, almost famous
and little known people, of serendipities, discoveries and re-discoveries. The discovery
of insulin has been a milestone and has truly revolutionized both the therapy and the
prognosis of the diabetes, one of the diseases most studied in the history of medicine,
whose first mentions trace back to a collection of ancient Egyptian, Indian and Chinese
textbooks. As stated by Colwell, the introduction of insulin has heralded the end of the
so-called “pre-insulin era” or “frustration era”, paving the way for a new era and clinical
advancements. The current review offers a broad, comprehensive overview of main steps
culminating into insulin discovery, including recent advancements such as personalized
and individualized insulin therapy.
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INTRODUCTION
The discovery of insulin represents an authentic breakthrough, characterized, at the same time, by
contrasts, controversies and disputes among scholars, as well as by great disappointments, failures
and hopes. It is the story of famous, almost famous and little known people (1), of serendipities,
discoveries and re-discoveries.
The discovery of insulin has been a milestone in that has truly revolutionized both the therapy
and the prognosis of the diabetes. This is one of themost studied diseases in the history of medicine,
whose first mentions trace back to a collection of Egyptianmedical texts written around 1552 before
Christ (BC), the so-called Ebers Papyrus (2–4), and to ancient Indian and Chinese textbooks. The
papyrus proposed as a treatment a 4-day course of a decoction of bones, wheat, grain, grit, green
lead and earth. The Indian physician, Sushruta, and the surgeon Charaka (400–500 AD) were able
to distinguish between a diabetes type 1 and a diabetes type 2, termed as “madhumeha” (literally,
‘honey urine’).
The term “diabetes” was probably introduced by the Greek physician Demetrius of Apamea
or by Aretaeus of Cappadocia (129-199 AD) from the Greek word “διαβn´της” (transliterated
“diab`¯ete¯s”), literally “passing through” and meaning “siphon” (5). The Roman physician Claudius
Galenus (125–199 AD) used the terms “diarrhea urinosa” and “dipsatos,” whereas Avicenna
(980–1037 AD), in “The Canon ofMedicine,” described abnormal appetite and gangrene in diabetic
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patients and proposed a mixture of seeds (lupin, fenugreek,
and zedoary) as a treatment. The term “diabetes mellitus” was
introduced in 1674 by the British physician ThomasWillis (1621–
1675) of the Iatrochemical School of medicine (6), for clinically
differentiating this disease from the diabetes insipidus, referring
to the particular sweetness of urine in diabetic patients (“quasi
melle aut saccharo inbuta”). Willis defined diabetes mellitus as
the “Pissing Evil.” Only in 1776, the Liverpool physician, natural
philosopher and experimental physiologist Matthew Dobson
(1732 or 1735–1784) (7) discovered that urine of diabetic patients
is sweet because of excess in sugar. He published this finding in
the “Medical Observations and Enquiries.”
Initially thought to be a kidney disorder, diabetes has been
correctly identified as a metabolic pathology. In 1988, during
the Banting’s lecture, the American endocrinologist Gerald M
Reaven, “father of insulin resistance” described the constellation
of symptoms now called metabolic syndrome or syndrome
X, linking together central obesity (male-type or apple-shaped
obesity), diabetes, hypertension, insulin resistance and impaired
glucose tolerance.
As stated by Colwell, the introduction of insulin has heralded
the end of the so-called “pre-insulin era” or “frustration era,”
paving the way for a new era and clinical advancements (8).
THE PRE-INSULIN ERA
This era is characterized by the efforts of controlling diabetes
by means of bizarre pharmacological treatment such as the
use of opium or dietary interventions, based on the conviction
that diabetic patients should eat extra-portion for compensating
their endocrinological and metabolic impairment. In the 1850s
the French physician Pierre Adolphe Piorry (1794–1879)
prescribed hyper-caloric diets for counteracting the urinary loss
of calories (8).
However, some physicians began to notice that it was
fasting and not an excess of calories to improve the clinical
symptoms of diabetes. In 1706, John Rollo, Surgeon-General
to the Royal Artillery, had successfully treated a patient
by dietary restriction. The French pharmacist and hygienist
Apollinaire Bouchardat (1809–1886), considered the modern
father of diabetology, observed an improvement of diabetic
patients during the German siege of Paris in 1870. His school,
which included the physician Bernhard Naunyin (1839–1925),
became famous for advising sugar-free diets, known as the
“Bouchardat’s treatment” (8). Other nutritional interventions
became extremely popular, such as the Allen diet, introduced
by the American physician Frederick Madison Allen (1879–
1964). It was a carbohydrate-restricted low-calorie diet (9),
described in a book entitled “Studies concerning glycosuria
and diabetes“ and published in 1913. The American physician
Elliott Proctor Joslin (1869–1962), founder of the Joslin
Diabetes Centre, one of first structures offering specialized
service to diabetic patients, was a fervent advocate of a
severe, prolonged fasting and of under-nutrition or under-
nourishment as a cure for diabetes, the so-called “starvation
diet” (9–12).
Insulin would have canceled away all these bizarre treatments,
including the oral “miraculous” pills termed metabolin and
irrebolin, proposed by Karl Loening in 1922 and by Ernst Vahlen
in 1924 (13).
TOWARD THE DISCOVERY OF INSULIN
Insulin is a peptide hormone, which is produced and released by
beta cells of the pancreatic islets, that finely tunes the metabolism
of carbohydrates, fats and protein inducing the uptake of glucose
from the blood into fat, liver and skeletal muscle cells. In
1910 and later in 1916, in London, Sir Edward Albert Sharpey-
Schafer (1850–1935) (14) described in depth that the pancreatic
islands are able to secrete a substance capable of controlling
glucose metabolism, which he termed “insulin,” from Latin
“insula” (“island”), with reference to the Langherans islands.
Other scholars attribute the invention of insulin to the Belgian
Jean de Meyer (1878–1934) in 1909.
The history of the steps leading to the discovery of insulin
overlaps, at least partially, with the history of diabetes and
of pancreatic anatomy. Pancreas (from Greek “piα`γ κρεας”,
literally “all-flesh”) was first identified by the Greek anatomist
and surgeonHerophilus (335–280 BC). This termwas introduced
by the Greek anatomist Rufus of Ephesus (late first century).
In 1869, the German pathologist, physiologist and biologist
Paul Langerhans (1847–1888) announced that pancreas has two
systems of cells (15). In 1875, the German physiologist and
histologist Rudolph Heidenhain (1834–1897) performed a study
on pancreas and its physiological functions, arriving to state
the so-called Heidenhain’s law, according to which glandular
secretion is always accompanied by modifications and alterations
at the level of the anatomic structure of the gland. Further,
he had shown that the fresh pancreatic juice was surprisingly
not characterized by any proteolytic power (16). This would
have been confirmed some years later, in 1902, in France, by
the physiologists Camille Délézenne (1868–1932) and Albert
Frouin working at the Pasteur Institute. They discovered the
enterokinases and characterized the function and activity of
the diastases of certain microbes, snakes, plants and poisonous
mushrooms (16). However, unfortunately, the discoverers of
insulin, Frederick Grant Banting (1891–1941) (17–19) and
Charles Herbert Best (1899–1978), ignored this, since they were
convinced that pancreatic extract should contain tryptolytic
enzymes.
In 1683, in Germany, the Swiss anatomist Johann Conrad
Brunner (1653–1727) performed the first pancreatectomy with
and without ductal ligation (20). It was however only in 1884
that the French Louis Vaillard (1850–1935) and Charles Louis
Xavier Arnozan (1852–1928) discovered that pancreatic duct
occlusion caused pancreatic atrophy without hyperglycaemia (8).
The closure of the ducts, in fact, led to necrosis of the pancreas,
with the exception of the Langerhans islands. This was exploited
in 1889 by the German physicians Joseph von Mering (1849–
1908) and Oskar Minkowski (1858–1931) (21) who conducted
experiments on total pancreatectomy in the dog.Minkowski tried
to cure diabetes by injecting pancreatic powder extracts. Further,
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von Mering was able to induce an experimental diabetes in
animals administering phloretin-2′-β-D-glucopyranoside (also
known as phloridzin, which actually has been further developed
into today’s sodium-glucose co-transporter type 2 or SGLT-2
inhibitors such as empagliflozin, canagliflozin, and dapagliflozin)
(22). The same experiments were repeated in Italy by Battistini
and Capparelli in 1892 and Vanni in 1895 who described results
apparently encouraging, but which were clinically non suitable
because of the toxicity of pancreatic extracts (23). Capparelli
injected triturated fresh pancreas extracts in 0.76% NaCl solution
in the abdominal cavity of a dog
In the United Kingdom, Mackenzie and Sibley came to the
same results and the same failures.
The Italian endocrinologist and pathologist Giulio Vassale
(1862–1913) described (24) that the ligation of Wirsung’s duct
resulted in atrophy of the esophageal pancreas, sparing the
Langerhans islands and, as such, not causing glycosuria. He
concluded that the islands had a specific and different function
from the rest of the pancreas.
In 1906, the American pathologist and anatomist Lydia Maria
Adams DeWitt (23, 24), after ligating the pancreatic ducts of
some cats, observed an exocrine pancreas atrophy and, from the
Langerhans islands, obtained a beneficial extract for diabetes,
which, despite the fact of not being optimal, maintained a discrete
glycolytic power. In 1908, the German physician George Ludwig
Zuelzer (1870–1949) (23, 24) found favorable results with the
administration of pancreatic alcohol extracts in diabetic patients.
In 1912, different scholars from many countries including the
Italian physicians Massaglia and Zannini (23, 24) came to the
conclusion that the destruction of the exocrine pancreas did not
produce any glycosuria, which, instead, was manifested after the
destruction of the Langerhans Islands.
This discovery led many researchers to use injections of
pancreatic extracts to cure diabetes. Studies also aimed at
discovering island separation techniques from the rest of the
pancreas, with several experiments conducted by Comby in 1892,
White in 1893, Johann Karl Goldscheider (1858–1935) in 1894,
Wilhelm Sandmeyer in 1895, Doyon in 1897, Hougounena and
Doyou in 1897, Hédon in 1898, Blumenthal in 1899, Hess in 1902,
Rennie and Fraser in 1907, Raphael Lépine (1840–1919) in 1909,
Pratt in 1910, Knowlton and Starling in 1911, the Professor John
Murlin and Kramer of the University of Rochester in 1913, Clark
in 1916, and Kleiner and Meltzer in 1919, among others (24).
The scientific community has undoubtedly underscored the
efforts and merits of the French physiologist and endocrinologist
Eugène Gley (1857–1930) (25–27) and of the Rumanian
physician Nicolae Constantin Paulescu (1869–1931) (28), who
were not sufficiently recognized for their contribution to insulin
discovery.
Eugène Gley was inspired by the hypothesis formulated by
the French histologist Gustave-Édouard Laguesse (1861–1927)
(29, 30) according to which the Langerhans islands secrete
a substance capable of preventing the elimination of glucose
through the urine. He decided to test this hypothesis with an
aqueous extract of pancreas, which was administered to diabetic,
pancreatectomized dogs. Gley noted that glycosuria was reduced
and the symptoms of diabetes significantly improved.
In order to find out whether, in the animals subject of
his experiment, the beneficial action was due to the exocrine
pancreas or rather to the action of the islands, he isolated the
tissue of the Langerhans islands in the form of an extract to
be injected in diabetic dogs. This administration significantly
improved and decreased glycosuria. This experiment would have
been repeated 25 years later by Banting and Best.
In 1971, Henderson at the question “Who discovered insulin?”
replied: “It’s about giving Gley themerit of it” (31). After finishing
his experiments, Gley wrote a report that sealed within an
envelope, which was handed over to the “Société Francaise de
Biologie” in 1905, with the recommendation to be opened only
upon his explicit request. After 1890, Gley no longer repeated his
experiments and only in 1921, when Banting and Best made their
discovery known in the world, Gley gave the order to open his
letter, realizing having discovered the insulin without knowing it!
Another important scholar who should be remembered in the
history of insulin discovery is Paulescu, who called it “pancreas”.
He studied medicine in Paris where he became assistant to
Étienne Lancereaux (1829–1910), who had described in depth the
clinical differences between diabetes type 1 and type 2 (“le diabète
maigre et le diabète gras”) in 1876 (32).
At the age of 31, in 1900, Paulesco returned to Bucharest:
despite the young age, he was already considered as an expert in
the field of endocrinological studies. In 1904, Paulesco became a
professor of physiology at the University of Bucharest until 1931,
when he died. As a student, in France, Paulesco was inspired
by Mering’ and Minkowki’s studies, which suggested that the
pancreas produced an anti-diabetic hormone.
In 1916, Paulescu, after studying the pancreatectomy in dogs,
concluded that the injection of aqueous solution of pancreatic
extract allowed an improvement in experimentally induced
diabetes.
However, the First World War, already in progress in 1916,
blocked Paulescu’s studies, which he was able to resume only in
1920 with new experiments whose results were published in 1921
in the journal “Archives Internationales de Physiologie.” Paulescu
removed the animal pancreas without ligating the excretory
ducts, then he emulsified the pancreatic tissue and injected it into
the jugular vein of the pancreatectomized dog. In this way, the
Romanian physician demonstrated that the extract of the dog and
ox pancreas contained some substances capable of acting with an
anti-diabetic effect.
However, a dilemma remained unsolved, whether it was
possible to separate the substance with anti-diabetic effect
produced by the Langherans islands from the rest of the pancreas.
The most used method was always the ligation of the ducts,
which would have been later replaced by the use of gelatin for the
occlusion of the ducts.
THE INSULIN ERA
Banting, a young Canadian orthopedic surgeon, grew up on a
small Ontario farm and initially decided to study for ministry
at the Victoria College, in Toronto, even though, after some
months, he interrupted the study of divinities for the medical
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studies. During the World War I, he enlisted in the Royal
Canadian Army Medical Corps in 1915, and graduated in
medicine in December 2016 after attending an accelerated 15-
month program. Banting served as a medical officer in England
and in France. He was awarded the Military Cross by the
British government, for his valorous conduct during the Cambrai
campaign (33).
In 1920, Banting, studying the work by Moses Barron (1884–
1974) entitled “The relation of the Islets of Langerhans to
Diabetes” and published in 1920, was struck by the description
of Vaillard’ and Arnozan’s experiments as well as by the work
of Ssobolew, published in this thesis entitled “Zur normalen
und pathologischen Morphologie der inneren Sekretion der
Bauchspeicheldrüse” on the binding of the pancreatic ducts in
rabbits, dogs and cats, in order to study the relationship between
pancreas and diabetes. Banting was also impressed by the work of
E.L. Scott, who, working at the Carlson’s laboratory in Chicago,
in 1912 came almost to the discovery of insulin, using an alcohol
extract, which led him to a step away from the discovery of
insulin.
As already mentioned, the difficulty encountered by all
scholars was to separate the extract of the Langerhans islands
from the rest of the pancreatic exocrine tissue. Banting at the
University of Toronto succeeded in this. Since November 1920,
Banting began working in a laboratory led by John James Richard
MacLeod (33). Banting’s goal was to isolate the hormone secreted
by the pancreatic islands. Before leaving for a planned holiday
in Scotland, MacLeod allowed Banting to be assisted by two
young assistants, Best and Noble (34). The researchers closed
the pancreatic ducts with a technique designed by Banting
to get the degeneration of the pancreatic exocrine tissue and
to obtain a pancreatic islet from the pure state. With this
liquid extract, for the first time, in the history of medicine,
Banting and Best found the way to control glucose in a diabetic
animal.
MacLeod, returning from Scotland, guessed the historical
importance of the results and, on 11th January 1922, he
authorized to conduct experimentation in humans.
Leonard Thompson, a 14-year-old, serious diabetic patient
at the Toronto General Hospital, was the first patient to be
treated. However, the initial clinical experimentation was a
failure: the administration of 15ml of pancreatic extract had
no impact on ketoacidosis, only slightly reducing glycemia and
glycosuria, and resulted in the formation of a sterile abscess.
On January 23rd Leonard underwent another series of injections
and this time he experienced a normalization of glycaemia,
glycosuria, and ketonuria. More in details, glycaemia decreased
from 520 mg/dl to 120 mg/dl. Glycosuria dropped from 71 to
9 g; ketonuria disappeared. The merit was also of the clinical
biochemist James Bertram Collip (1892–1965), who developed
a new extraction and concentration protocol. Collip, from the
alcoholic acid extract of oxen and pork pancreas, showed that
these preparations were more effective than those obtained by
the binding of the ducts and subsequent degeneration of the
esophagus pancreas.
Besides Leonard, Joe Gilchrist, a diabetic doctor, was another
patient who underwent the innovative treatment, and was also
the first patient to suffer from hypotensive hyperglycaemia, one
of the side-effects of insulin therapy.
On the basis of these successes, on 12th December 1921,
Banting and Best reported the results of the discovery of insulin
to the American Society of Physiology.
In 1923, a German pharmaceutical laboratory began
producing insulin, following the manufacturing license issued
by the Toronto Insulin Committee. In 1923, insulin production
began in Denmark and Austria, and, in 1924, in Hungary,
Australia and Argentina.
In 1923 Banting and MacLeod were awarded the Nobel Prize
for Physiology or Medicine. The prize aroused a lively and
debated controversy, in that Best, Collip, and Paulescu were
excluded. For compensating this, Banting and MacLeod decided
to divide their prize with Collip, whilst Noble and Paulescu were
officially excluded from the discovery of insulin (34).
CONTINUOUS EFFORTS FOR IMPROVING
THE QUALITY OF INSULIN
After 1921, scholars intensified their efforts to obtain pure
and crystalline insulin preparations. Banting and Best had
obtained, indeed short-acting insulin preparations, lasting about
6 h, with inevitable and subsequent peaks of hyperglycaemia and
glycosuria, within 24 h. The effort of the experimentations lead
to the production of a delayed-acting insulin to counteract both
hyperglycaemia and hypoglycaemia.
Hans Christian Hagedorn (1888–1971), who in 1923 formed
the Nordisk Insulinlaboratorium, and B.N. Jensen, N.N. Krarup
and J. Wodstrup produced in 1936 a slowly absorbed insulin in
Copenhagen, combining the hormone with protamine, a basic
protein. In 1939, David Aylmen Scott, in Toronto, created the
insulin–protamine zinco complex, whose glucose lowering effect
lasted up to 48 h.
In 1951–1952, the amorphous “lente” insulins (IZS)—
semilente, lente, and ultralente—were developed. In Denmark,
Knud Hallas-Møller, the chemical engineers Thorvald (1887–
1961) and Harald Pedersen and Jörgen Schlichtkrull, with his
method that combined re-crystallization of conventional insulin
and chromatographic procedures produced an insulin-slow,
protamine-free zinc. Later, the brothers Pedersen decided to
leave the Nordisk Insulinlaboratorium and established their own
pharmaceutical firm, the Novo Nordisk.
In 1955, the British biochemist Frederick Sanger (1918–2013)
managed to fully sequence the bovine insulin and discovered its
exact composition in terms of amino-acids. For this discovery,
Sanger won the Nobel for Chemistry in 1958. For the discovery of
the physical structure of insulin, the English biochemist Dorothy
Mary Crowfoot-Hodgkin (1910–1994), a pioneer in the protein
X-ray crystallography, was awarded the Nobel Prize in Chemistry
in 1964.
In 1956, the American physician and scientist Solomon
Berson (1919–1972), with the medical physicist Rosalyn Sussman
Yalow (1921–2011), two towering figures in the field of clinical
biochemistry, began to develop a radioimmunoassay (RIA) for
monitoring glycemia. The assay was successfully completed in
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TABLE 1 | Main events and steps in the history of the discovery of insulin.
Year Major event
1552 BC One of the earliest, if not the earliest, descriptions of diabetes
1675 Thomas Willis coins the expression “diabetes mellitus”
1682–1709 Johann Conrad Brunner observes polydipsia and polyuria in dogs
after partial pancreatectomy
1706 John Rollo, Surgeon-General to the Royal Artillery, treats a patient
by dietary restriction
1776 Matthew Dobson discovers that urine of diabetic patients is sweet
because of excess in sugar
1788 Thomas Crawley reports some clinical cases and links diabetes
with pancreatic dysfunctions
1850s French physician Pierre Adolphe Piorry introduces hypercaloric
dietary treatment
1857 French Claude Bernard links diabetes with excess glucose
production
1860s Claude Bernard reports extensive physiopathological mechanisms
of diabetes
1865 Introduction of the concept of “opotherapy” by Ancelet
1869 Paul Langerhans discovers cellular islets within the pancreas
Noyes reports a case of retinitis in diabetic patients
1870s Bouchardat postulates a link between pancreas and diabetes
1874 Kussmaul describes the air hunger of ketoacidosis in diabetic
patients
1875 Heidenhain demonstrates that extracts of the fresh pancreas
possess no proteolytic capacities
Nikolaus Friedreich postulates an indirect link between diabetes
and pancreatic disorders mediated by sympathtetic nerve ganglia,
in primis celiac ganglion and celiac plexus
1876 Étienne Lancereaux describes in depth the clinical differences
between diabetes type 1 and type 2
1889–1893 German physiologist Oskar Minkowski and physician Joseph von
Mering, show that if the pancreas is removed from a dog, the
animal gets diabetes
1892 Battistini and Capparelli try to cure diabetes by injecting pancreatic
powder extracts
1893 Laguesse terms the pancreatic cellular islets after Langerhans
(“islets of Langerhans”)
On December 20, 1893, Dr. P. Watson Williams in Bristol, England,
performs the first intervention of pancreas transplant
1898 Joslin proposes opium as treatment of diabetes
1901 Eugene L Opie correlates the hyaline degeneration of the islets of
Langerhans with the occurrence of diabetes
1906 Wilhelm Heiberg develops a method for counting the islets of
Langerhans and shows that they are low in diabetic patients
1907 J Rennie and T Fraser, from Aberdeen Royal Infirmary, experiment
the effect of extracts of pancreatic islets from various teleostei, in
particular the Lophius piscatorious, to a sample of 5 diabetic
patients
1908 Zuelzer experiments pancreatic extracts termed Acomatol
Zuelzer submits an application to the USA office of patents
1909 Forschbach publishes his findings of experiments with the
Zuelzer’s pancreatic extracts
1909–1910 Introduction of the name “insulin” by Belgian Jean de Meyer
1910 Joseph Pratt published “The relation of the pancreas to diabetes”
in JAMA
1912 Zuelzer takes out an American patent entitled “Pancreas
Preparation Suitable for the Treatment of Diabetes” (serial number
431,226)
(Continued)
TABLE 1 | Continued
Year Major event
1913 Murlin and Kramer propose that an optimal treatment of diabetic
patients should lead to the restoration of respiratory quotient
1914 Rose experiments an alkaline pancreatic extract
1915–1919 Meltzer and Kleiner experiment the effect of a pancreatic solution
highly diluted in NaCl
1916 Introduction of the name “insuline” by Sir Edward A
Sharpey-Shafer of Edinburgh
1918 Hagedorn and the pharmacist Bierger Norman Jensen publish a
micro-method for the determination of blood glucose
1920 Moses Barron publishes his “The relation of the islets of
Langerhans to diabetes, with special reference to cases of
pancreatic lithiasis”
1921 Dr Frederick Banting and medical student Charles Best perform
experiments on the pancreases of dogs in Toronto, Canada
Nicolae Paulescu presents his findings at the Rumanian Biological
Association and later publish them in the “Reports of the French
Society of Biology” and in the “Archives Internationales de
Physiologie”
Paulesco terms the impaired hormone in diabetic patients as
pancreatin
1922 Bovin insulin was first given injected to humans
Banting and Best publish their article entitled “The Internal
Secretion of the Pancreas” in the “Journal of Laboratory and
Clinical Medicine”
1923 Commercialization of Iletin
Banting and Macleod are awarded the Nobel Prize in Physiology
or Medicine
August Krogh brought insulin to Scandinavia
Petrén publishes his “Diabetes-studier”
1924 First attempt to graft pancreatic tissue to cure diabetes by the
English surgeon Frederick Charles Pybus
1925 One of the earliest, if not the earliest, mentions of the possibility of
administering insulin by breathing an aerosol
1926 JJ Abel obtains the first crystallization of insulin
1936 Sir Harold Percival (Harry) Himsworth introduces the concept of
insulin resistance
Protamine was utilized to produce a slow-release insulin: Hans
Christian Hagedorn introduced protamine insulin in Denmark
1949 Production of the first standardized insulin syringes
1951 Development of amorphous lente insulins (IZS)
1955 Sanger characterized the amino acid sequence of human insulin
1957 Introduction of the technique of immunoassay by Solomon Berson
and Rosalind Yalow
1959 Sanger is awarded the Nobel Prize in Chemistry
1960 First prototype of ambulatory insulin pump by Dr. Arnold Kadish
1963 Introduction of insulin pumps
1964 Dorothy Mary Crowfoot-Hodgkin is awarded the Nobel Prize in
Chemistry
1966 First successful transplantation of pancreatic tissue by the group
of Kelly
1967 Updike and Hicks realize an implantable miniature electrical
transducer of glucose
1970s Continuous subcutaneous insulin infusion (CSII)
1972 Introduction of the first standardized U100 insulin
1974 Development of monocomponent MC insulin or single peak insulin
Gérard Slama and colleagues in Paris show that a few days of
open-loop intravenous (IV) insulin infusion in type 1 diabetes using
a portable pump held in a shoulder bag produce good glycaemic
control
(Continued)
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TABLE 1 | Continued
Year Major event
1975 Synthesis of the first fully synthetic insulin CGP 12831
Lowy reports the clinical effectiveness of using SMBG in
pregnancy
1978 David Goeddel and colleagues of the biotechnology firm
Genentech use recombinant DNA techniques to produce synthetic
“human” insulin
Development of the first portable insulin pumps, the Autosyringe,
also named ‘Big Blue Brick’
1979 Introduction of the first needle-free insulin delivery system by
Derata
1980 Introduction of the “basal-bolus” concept and intensive insulin
therapy
1982–1983 Commercialization of the first insulins utilizing rDNA technology,
Humulin® R (rapid) and N (NPH, intermediate-acting)
1983 Commercialization of the Nordisk infuser
1985 Novo Nordisk introduces the Insulin Pen delivery system
1988 Gerald Reaven identifies and describes the constellation of
symptoms now called metabolic syndrome
1992 Medtronic releases the MiniMed 506 insulin pump
1993 The Diabetes Control and Complications Trial shows the linear
relation between the degree of glycemic control and complications
Commercialization of the first instant glucose tablets
1996 Approval of Lispro
2000 Approval of Aspart
2004 Approval of Glulisine
2005 Approval of Detemir
Approval of the buccal insulin, Oralin®
Approval of the venom of the lizard Gila monster, which contains
exendin 4, a molecule fostering one of the insulin-releasing
pathways
2006 Approval of Exubera, the first inhaled insulin
2008 Approval of the FreeStyle Navigator CGM from Abbott
2013 Rejection of Degludec
The University of Cambridge develops an artificial pancreas that
pairs the technology of an insulin pump with a continuous glucose
monitor
2015 Approval of Degludec
Dr Edward Damiano introduces the iLet
1961. For this, Yalow received the Nobel in Physiology or
Medicine in 1977, along with Roger Charles Louis Guillemin
(born in 1924) and Andrzej Viktor “Andrew” Schally (born in
1926).
In 1963 and 1965, independently P.G. Seeing in the USA,
Wangyu in the Popular Republic of China and H. Zahn, in
Western Germany were able to synthesize insulin.
Insulin discovery also aroused other discoveries, such as
glucagon, a hormone produced by the alpha cells of the
Langerhans Islands, with hyperglycaemic action, opposed to
that of insulin, discovered by the British C.W.A. Kimbell.
In 1973, Roger Guillemin identified somatostatin, a pituitary
polypeptide, capable of reducing the hyperglycaemia in insulin-
free diabetes. efforts to improve insulin lead to Allen’s myrtillin
(an anthocyanin, a 3-glucoside of delphinidin) and Collipìs
glucokinin.
Insulin purification techniques were improved until the
preparation of insulin with a human-like chemical structure.
Subsequently, human insulin was produced using the
recombinant DNA technique, thanks to the genetic modification
of bacteria.
In 1975, fully synthetic insulin (CGP 12 831) was synthesized
in the laboratories of Ciba-Geigy in Basel. Genentech rDNA
human insulin obtained on 24th August, 1978 from combination
of A and B chains individually expressed in E. coli. In 1980,
recombinant DNA human insulin was first tested in a sample
of 17 non diabetic volunteers, in England. The first diabetic
patient treated was Sandy Atherton, 37-year-old, from Wichita,
Kansas (USA). In 1982 other synthetic insulins, much more
less allergenic than animal insulins, became widely available to
diabetic patients, such as Humilin, manufactured by Eli Lilly.
On 10th April 1986 the approval to market BHI derived from
human proinsulin was signed. In the 1980-90s analog insulins
were produced, that is to say a genetically modified form of
insulin where the amino acid sequence has been altered in order
to optimize insulin absorption, distribution, metabolism and
excretion. In 1996, Eli Lilly introduced the first type of analog
insulin lispro under the brand name of Humalog. Aspart was
approved and released in 2000, while glulisine in 2004.
Concerning needle-free insulins, Exubera, the first inhaled
insulin, has been developed by Sanofi-Aventis and Pfizer and
marketed by Pzifer in 2006. The idea of administering insulin
by breathing an aerosol can be found for the first time in
1925 and has been subsequently relaunched in 1971 (35–37).
Investigations carried out by Pfizer Inc. in partnership with
Nektar on aerosolized formulations led to the development of
a dry powder with appropriate particulate characteristics for
deposition in the alveoli. Inhaled insulin has low bioavailability
(about 9% of the amount inhaled) but results in adequate serum
insulin levels, therefore being as effective as subcutaneously
administered insulin at controlling glucose levels in both type 1
and type 2 diabetes. However, in October 2007 Pfizer decided to
cease sales of the product. Insulin delivered through the AERx
insulin Diabetes Management System AERx iDMS (Aradigm,
Hayward, CA), or other delivery systems, such as ProMaxx, AIR,
Spiros, and Technosphere/Afrezza (MannKind, Danbury, CT)
and Solo products with inhaled insulin (38–49).
Another promising product is the buccal/oral insulin. Oralin
was approved in 2005 in Ecuador and marketed by Generex
uses RapidMist technology to deliver a mixture of insulin,
surfactants and lipids to buccal mucosa (50). Further advances
in technology include the Emisphere technologies, such as the
Eligen technology, and the Nobex technology, which is able
to deliver covalently modified insulin, namely hexyl insulin
monoconjugate 2 (HIM2) across membranes (51).
TOWARD PERSONALIZED INSULIN
THERAPY
After the discovery of insulin and its synthesis, another important
step was to make the patient share with the physician the insulin
therapy, that is to say to acquire the ability to control one’s own
blood and urine with glucose dosage, in such a way that the
treatment and the management become truly personalized. With
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this regard, it should be briefly mentioned the development of
reactive strips to control glycaemia, glycosuria and acetonuria,
which have made diabetic patients protagonists in the daily
management of their disease. In 1963 Dr. Arnold Kadish of
Los Angeles, California, designed the first insulin pump to be
worn, which had more or less the size of a Marine backpack
(52). In 1979, Al Mann CEO of PaceSetter Systems became
interested in insulin pumps. In 1983, MiniMed introduced the
model 502. In1986 MiniMed introduced the so-called “insulin
friendly tubing.” In 1992, in 1996 and in 1999,MiniMed launched
themodels 506, 507C and 508, respectively. In 2001MiniMedwas
acquired by Medtronic.
In 1967, Updike and Hicks realized a miniature electrical
transducer of glucose and implanted it in an animal in order
to monitor glucose continuously (53). In the 1970s, the group
of John Pickup and Harry Keen (54, 55) as well as the group
of Tamborlane (56) proposed the continuous intra-cutaneous
injection of insulin (CSII). In the following years, other groups
refined this approach and tried to close the loop integrating
the pump and the continuous glucose monitor (CGM): namely,
Albisser (57), Pfeiffer (58), Mirouze (59), Kraegen (60) and
Shichiri (61), among others. The combination of CSII with CGM
devices results into sensor augmented pumps (SAPs). As of today,
there are more than 140 trials on closed loop pumps, including
intra-peritoneal or dual hormone pumps.
An individualized approach of insulin therapy can improve
glycemic control, minimizing hypoglycemic risk and side-effects,
conjugating patient preferences and increasing adherence to
treatment (62).
THE POST-INSULIN ERA: BEYOND
INSULIN?
The dream of Banting was to transplant pancreas in humans (63).
The first who attempted to graft pancreatic tissue to cure diabetes
was the English doctor P. WatsonWilliams from Bristol, who, on
the 20th December 1893, grafted three fragments of a pancreas
obtained from a sheep into the subcutaneous tissue of a 15-year-
old boy suffering from diabetes (64, 65). The English surgeon
Frederick Charles Pybus (1883–1975), from Newcastle-on-Tyne,
reported unsuccessful attempts in 1916–1924 (66, 67). The first
successful transplantation of pancreatic tissue was a whole organ
pancreas transplant in 1966 carried out by the group of Kelly (65).
Artificial pancreas (AP) is another promising approach to go
beyond insulin. Cobelli and coworkers (68) have defined AP as
a “closed-loop control of blood glucose in diabetes, is a system
combining a glucose sensor, a control algorithm, and an insulin
infusion device.” So far, only one type of bedside-type artificial
endocrine pancreas is currently available: STG-22 (Nikkiso Co.
Ltd., Japan) (69).
In conclusion, the discovery of insulin is not only a milestone
in the history of medicine—still ongoing (Table 1)—but also an
important lesson, with different, both historical and bioethical
implications (70).
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